Tissue-based genomic classifier tests, developed to improve prostate cancer risk assessment and treatment recommendations, ...

M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

In this systematic review, ten studies reported risk reclassification of prostate cancer with genome classifier testing, with ...

The Swedish biotech hopes its precision therapy will help patients with advanced solid tumors who currently have few ...